Table 4.
Treatment-related adverse events and causes of chemotherapy interruptions
| FOLFIRINOX (n = 371) | Gemcitabine/nab-paclitaxel (n = 157) | P value | FOLFIRINOX (n = 151) | Gemcitabine/nab-paclitaxel (n = 151) | P value | |
|---|---|---|---|---|---|---|
| Treatment-related adverse events | ||||||
| Anemia ≥3 | 70 (18.9) | 50 (31.8) | < 0.01 | 29 (19.2) | 50 (33.1) | 0.01 |
| Thrombocytopenia ≥3 | 48 (12.9) | 15 (9.6) | 0.27 | 22 (14.6) | 15 (9.9) | 0.22 |
| Neutropenia ≥3 | 181 (48.8) | 70 (44.6) | 0.38 | 78 (51.7) | 67 (44.4) | 0.21 |
| Neutropenic fever | 48 (12.9) | 10 (6.4) | 0.03 | 15 (9.9) | 10 (6.6) | 0.30 |
| Granulocyte colony stimulating factor | 304 (81.9) | 10 (6.4) | < 0.001 | 130 (86.1) | 9 (6.0) | < 0.001 |
| Peripheral neuropathy | 56 (15.1) | 40 (25.5) | < 0.01 | 25 (16.6) | 38 (25.2) | 0.07 |
| Cause of chemotherapy interruption | 25 (6.7) | 46 (29.3) | < 0.001 | 12 (7.9) | 35 (23.2) | < 0.001 |
| General weakness | 21 (5.6) | 22 (14.0) | 10 (6.6) | 19 (12.6) | ||
| Peripheral neuropathy | 0 | 15 (9.6) | 0 | 8 (5.3) | ||
| Peripheral edema | 0 | 3 (1.9) | 0 | 3 (2.0) | ||
| Uncontrolled diarrhea | 1 (0.3) | 1 (0.6) | 0 | 1 (0.7) | ||
| Drug-induced pneumonitis | 0 | 2 (1.3) | 0 | 1 (0.7) | ||
| Bone marrow suppression | 3 (0.8) | 1 (0.6) | 2 (1.3) | 1 (0.7) | ||
| Others (pneumonia, tumor bleeding) | 0 | 2 (1.3) | 0 | 2 (1.4) | ||